Dr Ranjit Manchanda MD, MRCOG, PhD
Clinical Senior Lecturer & Consultant Gynaecological Oncologist
Bartshealth NHS Trust, Royal London Hospital
Trial Coordinator: Dhivya Chandrasekaran
Clinical Research Fellow in Gynaecological Oncology
Barts Cancer Institute, Queen Mary University of London
Clinical trial locations
Genetic testing in ovarian cancer patients is now being implemented across the NHS and offers genetic testing to patients diagnosed with certain types of cancer affecting the ovary, fallopian tube or peritoneum. It is hoped that by doing this, patients across the NHS will have even better treatments and that in some families, cancers will be prevented.
About the trial
The trial offers a genetic test to women with certain types of ovarian cancer. This is to detect gene alterations that may be a cause of ovarian cancer. The test will look for alterations in the following genes: BRCA1, BRCA2, RAD51C, RAD51D and BRIP1. At present, testing for changes in the genes BRCA1 and BRCA2 is standard practice. However, testing for the additional genes (RAD51C, RAD51D, BRIP1) is limited to a small number of units.
The trial will also find out how women feel about genetic testing and the impact this may have on their psychological well being and quality of life.
There are three parts to this study. You do not have to take part in all aspects of this study.
Part 1. The impact of genetic testing on emotional wellbeing and quality of life.
Part 2. The use of blood and tumour tissue that will include testing for genetic and non-genetic factors that affect ovarian cancer.
Part 3. The storage of blood and/or tumour tissue for future research
Who can take part?
This trial is for women with epithelial non-mucinous ovarian cancer, high grade fallopian tube cancer, and primary peritoneal cancer who have been offered genetic testing in relation to ovarian cancer.